Convertible CAR-T (lead candidate)
Pre-clinical- Indications
- Cancer
Company intelligence / Profile preview
Xyphos Biosciences, Inc.
South San Francisco, California, United Statesxyphosinc.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Xyphos’ lead programs are based on its proprietary convertibleCAR™ cell therapy platform. The company’s first product candidates have been in preclinical development with plans for first-in-human studies. No published clinical results as of May 2025[6][10].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Cell therapies (CAR-T cells)Bispecific antibodiesLentiviral vectors
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Parker Institute for Cancer Immunotherapy[5][6]Phanes Therapeutics[9]VIVEbiotech[9]Kelonia Therapeutics via Astellas partnership[4]
Beyond the preview
Go deeper on Xyphos Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Xyphos Biosciences, Inc..